ImpriMed co-founders Sungwon Lim and Jamin Koo met as undergraduates and discovered a shared passion for developing advanced technologies to improve the treatment of disease. Both went on to complete PhDs in engineering sciences at Stanford University, where they decided to launch a startup company to tackle one of the greatest challenges in human disease: cancer.
Rather than focusing on the development of new drugs for future patients, they built a platform that enables oncologists to quickly identify which of the available drugs can provide the best clinical outcomes for current patients. The ImpriMed platform combines quantitative high-throughput lab testing and artificial intelligence (AI) to provide healthcare providers with a comprehensive personalized drug prediction profile. Our AI models are trained using ImpriMed’s proprietary database of real-world clinical outcomes and a suite of lab tests that include our innovative ex vivo drug sensitivity assay that measures how a patient’s live tumor cells respond to a panel of anticancer drugs.
We first launched the ImpriMed platform in the veterinary oncology space which moves at a significantly higher speed than the human oncology market and allows easy access to comprehensive patient data. ImpriMed has helped 200+ veterinary oncologists in 30 states to deliver personalized treatments to their canine lymphoma and leukemia patients. Apart from providing veterinarians with a cutting-edge tool to help man’s best friend, ImpriMed’s experience in the veterinary market has paved the way for the company to launch its validated platform into the human oncology space.